<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33120727</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>43</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>23</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>The efficacy and safety of Chinese herbal compound combined with western medicine for amyotrophic lateral sclerosis: A protocol for systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>e21933</StartPage><MedlinePgn>e21933</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e21933</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000021933</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Traditional Chinese medicine (TCM) compound formulations are selected according to different populations, with strong targeting and less adverse reactions. As a complex disease, amyotrophic lateral sclerosis (ALS) has limited efficacy in the use of conventional treatment regiments, short life cycle, high cost, many side effects, and low quality of life. It is urgent to seek new alternative therapies. Clinical practice shows that Chinese herbal compound combined with western medicine has certain therapeutic advantages, but there is no evidence of evidence-based medicine. The purpose of this study was to evaluate the efficacy and safety of Chinese herbal compound combined with western medicine in the treatment of ALS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Use computer to retrieve English database (PubMed, Embase, Web of Science, the Cochrane Library) and Chinese database (CNKI, Wanfang Database, Weipu database, and China Biomedical Literature Service System), moreover manually retrieve Baidu academic and Google academic from the establishment of the database to 2020 July for randomized controlled clinical study on ALS treated with compound Chinese medicine with western medicine therapy, 2 researchers independently conducted data extraction and literature quality evaluation on the quality of the included studies, and meta-analysis of the included literature was carried out using RevMan5.3 software.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This study evaluated the efficacy and safety of TCM combined with western medicine in the treatment of ALS by means of effective rate, improved Norris scale, ALS Functional Rating Scale, TCM syndrome score, and adverse reaction incidence.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study will provide reliable evidence for the clinical application of Chinese herbal compound combined with western medicine in the treatment of ALS.OSF registration number: DOI 10.17605/OSF.IO/R5XG4.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Lei</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-6373-2063</Identifier><AffiliationInfo><Affiliation>Shaanxi University of Chinese Medicine, Xixian New Area.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Mingliang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Yan'an Municipal Hospital of Traditional Chinese Medicine, Yan'an, Shaanxi Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Shengjie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008516" MajorTopicYN="N">Medicine, Chinese Traditional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="Y">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078202" MajorTopicYN="Y">Systematic Reviews as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>30</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33120727</ArticleId><ArticleId IdType="pmc">PMC7581109</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000021933</ArticleId><ArticleId IdType="pii">00005792-202010230-00003</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Campanari ML, et al. Diagnostic challenge and neuromuscular junction contribution to ALS pathogenesis. Front Neurol 2019;10:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6372519</ArticleId><ArticleId IdType="pubmed">30787905</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai M, Yang EJ, et al. Complementary and alternative medicine for treating amyotrophic lateral sclerosis: a narrative review. Integr Med Res 2019;8:234&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6806396</ArticleId><ArticleId IdType="pubmed">31692669</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009;10:310&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali J, Sabrina P, Paul ES. Trials of anti-diabetic drugs in amyotrophic lateral sclerosis: proceed with caution? Neurodegener Dis 2014;13:205&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435550</ArticleId><ArticleId IdType="pubmed">24107404</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010;81:385&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC1, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, et al. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci 2019;13:1310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, et al. Clinical research on traditional Chinese medicine compounds and their preparations for amyotrophic lateral sclerosis. Biomed Pharmacother 2017;96:854&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">29078263</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, et al. A review of experimental research on herbal compounds in amyotrophic lateral sclerosis. Phytother Res 2014;28:9&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">23519768</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Gao JP, Guo YM, et al. Clinical efficacy of Fuyuan Shengji granule in improving TCM syndromes in patients with ALS. J Neurol Neurorehabil 2009;6:173&#x2013;5.</Citation></Reference><Reference><Citation>Wen LL, Li YQ, Shen JQ, et al. Clinical study on treating amyotrophic lateral sclerosis of lung and spleen deficiency with Jianpi Yifei decoction combined with western medicine. J Guangzhou Univ Tradit Chin Med 2019;36:1694&#x2013;8.</Citation></Reference><Reference><Citation>Su GL, Zhang JS, Hong Y. Treatment of 25 cases of amyotrophic lateral sclerosis with Yiqi Qiangji decoction. Chin J Integr Med on Cardio-Cerebrovasc Dis 2006;4:452&#x2013;3.</Citation></Reference><Reference><Citation>Pan WD, Su XJ, Wang J, et al. A randomized open clinical trial of invigorating spleen and invigorating qi in the treatment of amyotrophic lateral sclerosis. Acad J Shanghai Univ Tradit Chin Med 2013;27:38&#x2013;41.</Citation></Reference><Reference><Citation>Bao J, Fu MD, Shen BJ, et al. Clinical study on treatment of amyotrophic lateral sclerosis with Jiawei Sijunzi decoction. Herald Med 2016;35:43&#x2013;5.</Citation></Reference><Reference><Citation>Lacomblez L, Bouehe P, Bensimon G, et al. A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology 1989;39:1635&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">2685660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: arevised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci 1999;169:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>J.G. Zhao, X.T. Zeng, J. Wang, and L. Liu. Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis, JAMA, vol. 318, 2466-2482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5820727</ArticleId><ArticleId IdType="pubmed">29279934</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, et al. Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China 2016;8:246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5075535</ArticleId><ArticleId IdType="pubmed">27822184</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 2019;39:733&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>McGown AMJ. E o o d d Stopford High-throughput drug screens for amyotrophic lateral sclerosis drug discovery 2018;13:1015&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">30317895</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, et al. ALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment? Front Aging Neurosci 2017;9:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, Song Z, Li X, et al. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis. Neurol Sci 2018;40:235&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">30483992</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan P, Zhao D. Advances in diagnosis and treatment of amyotrophic lateral sclerosis. J Med Forum 2019;40:171&#x2013;4.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>